- Oyster Point Pharma, Inc.

Oyster Point Pharma Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial of OC-01 (varenicline) Nasal Spray for Patients with Neurotrophic Keratopathy

Read more about Oyster Point Pharma Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial of OC-01 (varenicline) Nasal Spray for Patients with Neurotrophic Keratopathy

Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic Diseases

Read more about Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic Diseases

Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF™) Gene Therapy to Target Ocular Surface Diseases

Read more about Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF™) Gene Therapy to Target Ocular Surface Diseases

Oyster Point Pharma Reports First Quarter 2021 Financial Results and Recent Business Highlights

Read more about Oyster Point Pharma Reports First Quarter 2021 Financial Results and Recent Business Highlights

Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting

Read more about Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting

Oyster Point Pharma to Report First Quarter 2021 Financial Results on May 6, 2021

Read more about Oyster Point Pharma to Report First Quarter 2021 Financial Results on May 6, 2021

George Eliades

Member of the Compensation Committee

George Eliades

Oyster Point Pharma Announces New Appointment to Board of Directors

Read more about Oyster Point Pharma Announces New Appointment to Board of Directors

Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

Read more about Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference

Read more about Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference

Information Requests

© 2021 Oyster Point Pharma, Inc. Oyster Point^™ and the Oyster Point logo are trademarks of Oyster Point Pharma, Inc.